|
USA-IL-KENILWORTH Azienda Directories
|
Azienda News:
- Home - Scancell
Scancell is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers
- Investors - Scancell
Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK
- Scancell Holdings plc (“Scancell” or the “Company”)
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapy products for the treatment of multiple cancers, today announces its interim results for the six months ended 31 October 2024 and provides a business update on progress achieved to date Highlights (including post period): SCIB1 iSCIB1+ (SCOPE trial)
- th January 2025 - scancell. co. uk
Scancell Holdin s plc (AIM: SCLP), a clinical-sta e biopharmaceutical company developin novel immunotherapies or cancer, has achieved si nificant clinical and commercial milestones in its ModiFY study
- Scancell Holdings plc (“Scancell” or the “Company”)
Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant
- Scancell Holdings plc
Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in
- Scancell Holdings plc Partnership with NHS Cancer Vaccine Launch PadE . . .
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapy products for the treatment of multiple cancers, announces a partnership with the NHS Cancer Vaccine Launch Pad(CVLP) to fast-track access for NHS patients into the fourth cohort of the Company’s Phase 2 clinical SCOPE
- Scancell Holdings plc Scancell to present translational data from the . . .
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapy products for the treatment of multiple cancers, announce translational data from the SCOPE trial demonstrating SCIB1 combined with
- Scancell Holdings plc Results for the Year Ended 30 April 2024
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer, today announces its final audited financial results for the year ended 30 April 2024 as well as a business
- Scancell Holdings plc
Scancell Holdings plc CHAIRMAN’S STATEMENT for the year ended 30 April 2021 _____ 5 · Increase the potency of the T cell response in Scancell’s COVID-19 vaccine which in turn should lead to improvements in long-term protection and immunological memory
|
|